Press Release BioMarin Announces Results From Phase 2 Clinical Study of 6R-BH4 in Poorly Controlled Hypertension
Press Release BioMarin Announces Offering of $450 Million of 0.599% Senior Subordinated Convertible Notes Due 2024
Press Release BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations
Press Release BioMarin to Host Third Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, October 28 at 5:00 p.m. ET (23:00 CET)
Press Release Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan
